Navigation Links
AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
Date:2/13/2008

NEW YORK, Feb. 13 /PRNewswire/ -- In response to the recent news of the U.S. Food and Drug Administration (FDA) "Early Communication" regarding a safety review of botulinum toxins in the United States, the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) wants to make clear that the FDA's inquiry relates primarily to high dose medical uses of BOTOX(R), and not BOTOX(R) Cosmetic for aesthetic use.

BOTOX(R) (botulinum toxin type A) is indicated and used to treat a variety of often serious medical conditions, whereas BOTOX(R) Cosmetic is approved by the FDA for the aesthetic treatment of wrinkles between the brows and involves very different doses.

On February 8th, the FDA announced it was reviewing certain serious adverse events following the use of botulinum toxins, particularly for the management of juvenile cerebral palsy. However, the FDA made clear in its communication that "the posting of this information does not mean that there is a causal relationship between the products and the adverse events."

The AAFPRS further clarifies that the adverse side effects under investigation by the FDA occurred in children with cerebral palsy where the therapeutic benefit of using BOTOX(R) was achieved in doses that were 15-20 times the dose used for cosmetic purposes.

"In all of the years BOTOX(R) Cosmetic has been used for cosmetic purposes, there have been no reported deaths linked to its use," says Vito Quatela, president of the AAFPRS. "With all of our members' combined experience with the drug, we are confident that the product is safe, effective and recommend its continued use as indicated. The FDA has been clear that it is not recommending discontinued use of BOTOX(R) Cosmetic and that there is no defect with the drug."

The AAFPRS reminds patients and professionals that all facial plastic and reconstructive surgeries should be performed by a board certified and experienced facial plastic surgeon. The AAFPRS cautions that all procedures have the potential for adverse events and complications. Physicians should have a proper medical history of a respective patient prior to treatment. Patients should be fully informed and educated about benefits and risks.

About AAFPRS

The American Academy of Facial Plastic and Reconstructive Surgery is the world's largest specialty association that represents over 2,700 facial plastic and reconstructive surgeons throughout the world. The AAFPRS is a National Medical Specialty Society of the American Medical Association (AMA), and holds an official seat in both the AMA House of Delegates and the American College of Surgeons board of governors. AAFPRS members are board certified surgeons whose focus is surgery of the face, head, and neck. In addition, the AAFPRS provides consumers with free information and brochures and a list of qualified facial plastic surgeons in their area by visiting the AAFPRS Web site, http://www.aafprs.org.


'/>"/>
SOURCE The American Academy of Facial Plastic and ReconstructiveSurgery
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Massachusetts Teacher Facing Unaffordable Mandatory Health Insurance Speaks Out Against CA Mandate Proposal
2. National Institute on Drug Abuse Director Nora Volkow Speaks about the Dangers of Narcotics on Azteca Americas Political Forum Issues: Caras y Voces
3. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
4. CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty
5. Autism Speaks Applauds Supreme Court Decision Upholding Families Right to Challenge IEPs Without First Trying Out School District Proposed Placement
6. Women for Women International Congolese Country Director, Christine Karumba, Speaks Out About the Rape Epidemic in the Democratic Republic of the Congo.
7. General Colin Powell Speaks Out for Prostate Cancer Prevention
8. Arizona Nurses Rally at Capitol for Patient Safety - Thursday
9. New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety
10. JPMA on the Safety of Baby Bottles
11. Patient Safety Awareness Week March 2 to March 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: